Welcome to our dedicated page for DOSEOLOGY SCIENCES news (Ticker: DOSEF), a resource for investors and traders seeking the latest updates and insights on DOSEOLOGY SCIENCES stock.
The DOSEF news page on Stock Titan provides a focused view of Doseology Sciences Inc., a biotechnology-driven consumer products company whose disclosures highlight IP-backed oral stimulant technologies and functional mushroom-based nutraceuticals. Company news offers insight into how Doseology presents its strategy across product development, regulatory planning, manufacturing and capital markets.
Recent releases describe Doseology’s work on precision-formulated oral stimulants and oral pouch technologies, including a partnership with McKinney Regulatory Science Advisors to guide formulation strategy, data generation, PMTA preparation and post-market compliance. News items also cover the company’s confidential manufacturing agreement, executed through its subsidiary Doseology USA Inc., with a North American partner operating an FDA-registered, GMP-certified and ISO 9001:2015-approved facility for oral pouch production.
Investors following DOSEF news can track updates on regulatory initiatives, manufacturing milestones and commercialization readiness for oral stimulant pouches, as well as Doseology’s commentary on consumer trends toward cleaner, controlled oral delivery formats. Earlier news provides context on the company’s evolution from a life sciences and mental health wellness focus, including functional mushroom tinctures, powders and supplements, to its current emphasis on biotechnology-driven consumer products.
Additional coverage includes capital-markets developments and investor communications, such as uplisting to the OTCQB Venture Market, DTC eligibility in the United States, and the launch of an Investor Communications Initiative with external advisory firms. Governance and management changes, strategic review announcements and facility decisions are also documented. For readers researching Doseology stock, this news feed serves as an organized archive of the company’s public statements on strategy, operations and market positioning.
Doseology Sciences Inc. (OTCQB: DOSEF) announced the appointment of Pratik (Tiki) Patel as the new Chief Financial Officer, effective March 3, 2023. Patel, a Chartered Professional Accountant with over 15 years of experience, replaces Peter Geh, who was thanked for his contributions. The CEO, Ralph Olson, expressed enthusiasm for Patel's financial expertise, emphasizing its potential positive impact on the company. Doseology focuses on mental health and wellness by developing innovative nutraceutical products utilizing functional fungi. The company aims to address mental health issues through its product line, available on its official website.
Doseology Sciences Inc. (CSE: MOOD, OTCQB: DOSEF) announced the termination of its lease in
Doseology Sciences Inc. has announced its approval for uplisting to the OTCQB Venture Market, effective July 6, 2022. Starting today, their shares will trade under the symbol DOSEF in the United States. This uplisting aims to enhance visibility and liquidity for investors. Doseology, which focuses on mental health and wellness through innovative products derived from functional fungi and plants, will continue trading on the Canadian Securities Exchange under the symbol MOOD and on the Frankfurt Stock Exchange as VU7.
Doseology Sciences Inc. has announced that its common shares are now approved for trading on the OTC Pink Open Market in the US under the symbol DOSEF. They will continue trading on the Canadian Securities Exchange and Frankfurt Stock Exchange under symbols MOOD and VU7 respectively. Furthermore, the Company applied for uplisting to the OTCQB Market. Doseology's shares also received eligibility for book-entry services through the Depository Trust Company, which is expected to enhance trading liquidity and accessibility for American investors, facilitating easier transactions.